Drug Trial Radar · NCT07396337
Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.
Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Jan 19, 2026
Primary completion
Oct 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of QHRD106 injection in treating acute ischemic stroke.
Conditions
- Acute Ischemic Stroke
Interventions
QHRD106 Injection (Low-dose group)Drug
Participants will receive QHRD106 injection (5600 IU) every 7 days with a total of 3 doses.
QHRD106 Injection (Middle-dose group)Drug
Participants will receive QHRD106 injection (8400 IU) every 7 days with a total of 3 doses.
QHRD106 Injection (High-dose group)Drug
Participants will receive QHRD106 injection (12600 IU) every 7 days with a total of 3 doses.
PlaceboDrug
Participants will receive placebo every 7 days with a total of 3 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- modified rankin scale (mRS) score ≤ 1Time frame: Day 90 after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.